Heat Biologics Cash Flow - Quarterly (NASDAQ:HTBX)

Add to My Stocks
$1.89 $0.02 (1.07%) HTBX stock closing price Sep 18, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Heat Biologics needs to disclose. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Heat Biologics profits and Heat Biologics debt. Heat Biologics stock analysis shows negative net income cash flow of $-7.98M till 2018 Q2. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Heat Biologics has a positive cash and cash equivalents change of $14.9M.

View and download details of Heat Biologics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-4.97M-0.49M5.86M-1M--0.01M-1.51M-2M-1.61M-0.5M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.06M---------
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.47M-0.41M-0.06M-0.06M-0.01M-0.01M-0.04M-0.04M-0.04M-0.03M
Acquisition Disposition of Subsidiaires---0.46M-0.46M-0.46M-----
Increase (Decrease) in Investments------6.65M6.65M6.65M4.8M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares29.11M3.57M9.09M6.64M6.64M6.54M17.23M12.08M6.28M6.28M
Issuance (Repayment) of Debt Securities-------6.94M-3.91M-1.61M-0.8M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-2.05M-0.17M-0.32M-0.23M-0.23M-0.21M-0.48M-0.38M-0.19M-0.19M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---0.01M-0.02M--0.06M--0.09M-0.02M-0.08M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year9.77M7.84M4.93M3.71M4.56M-----
Cash & Equivalents at Year End24.66M8.96M9.76M4.28M8.34M11.12M7.84M8.46M7.11M9.97M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Heat Biologics stock comparison chart provides an easy way to compare the stock price with peers along with details of Heat Biologics stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Heat Biologics has cash of $24.66M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Heat Biologics stock price.
  • Heat Biologics decreased its cash from operating activities to $-11.77M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-0.47M for HTBX stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $27.06M for Heat Biologics.

Key Financial Ratios For Heat Biologics Cash Flow

Quarterly Cash Flow Statements For Heat Biologics Inc Peers

Aduro BioTech cash flow, Advaxis cash flow, Celgene cash flow, SOLENO THERPTCS cash flow